Find therapies in clinical trials near you – page 4

Study on the Safety and Effectiveness of Azacitidine and Pembrolizumab for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer After Platinum Treatment

Study on the Safety and Effectiveness of Azacitidine and Pembrolizumab for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer After Platinum Treatment

Study of venetoclax and azacitidine combination treatment for acute myeloid leukemia patients with measurable residual disease after chemotherapy or before stem cell transplant

Study of venetoclax and azacitidine combination treatment for acute myeloid leukemia patients with measurable residual disease after chemotherapy or before stem cell transplant

Study of IMGN632, Venetoclax, and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Study of SY-1425 (tamibarotene) alone or with azacitidine in adult patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Study of SY-1425 (tamibarotene) alone or with azacitidine in adult patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Study on Continued Treatment with Sabatolimab for Adults with High-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Unfit for Chemotherapy

Study on Continued Treatment with Sabatolimab for Adults with High-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Unfit for Chemotherapy

Study on the Safety and Effectiveness of Azacitidine and Venetoclax for Patients with Higher-Risk Chronic Myelomonocytic Leukemia (CMML)

Study on the Safety and Effectiveness of Azacitidine and Venetoclax for Patients with Higher-Risk Chronic Myelomonocytic Leukemia (CMML)

Study of Relatlimab, Nivolumab, and 5-Azacytidine for Acute Myeloid Leukemia in Patients Not Eligible for Intensive Chemotherapy

Study of Relatlimab, Nivolumab, and 5-Azacytidine for Acute Myeloid Leukemia in Patients Not Eligible for Intensive Chemotherapy

Study on Venetoclax, Azacitidine, and Donor Lymphocyte Infusion for Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Relapse After Transplantation

Study on Venetoclax, Azacitidine, and Donor Lymphocyte Infusion for Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Relapse After Transplantation

Study of Galinpepimut-S compared to standard therapy for patients with acute myeloid leukemia who achieved complete remission after second-line treatment

Study of Galinpepimut-S compared to standard therapy for patients with acute myeloid leukemia who achieved complete remission after second-line treatment

Study of Ivosidenib and Azacitidine for Patients Aged 18 and Older with Untreated Acute Myeloid Leukemia with IDH1 Mutation

Study of Ivosidenib and Azacitidine for Patients Aged 18 and Older with Untreated Acute Myeloid Leukemia with IDH1 Mutation

Study of Venetoclax and Azacitidine for Maintenance Therapy in Patients with Acute Myeloid Leukemia in First Remission After Chemotherapy

Study of Venetoclax and Azacitidine for Maintenance Therapy in Patients with Acute Myeloid Leukemia in First Remission After Chemotherapy

Study of BLU-263 and Azacitidine for Patients with Advanced Systemic Mastocytosis and Other KIT Altered Blood Cancers

Study of BLU-263 and Azacitidine for Patients with Advanced Systemic Mastocytosis and Other KIT Altered Blood Cancers